Treatment of 116 cases of facial pigmented spots by auricular needle-embedding method

以耳穴子宫、神门、内分泌、肺为主穴,根据辨证选取配穴,埋针治疗面部色素斑患者116例,全部治愈.     

Dr. YIN Ming＇s Experience in Treating Pediatric Diseases

Dr. YIN Ming is skilled at the pediatric diseases and wins the trust from her patients and their families. I learned a lot from the clinical practice with her and now the experience is as follows.     

Observation on therapeutic effect of cold moxibustion on rheumatoid interphalangeal arthritis

目的:观察冷灸对类风湿性指间关节炎的临床疗效.方法:将576例类风湿性指间关节炎随机分为冷灸组290例和对照组286例,治疗时间为2个月.结果:两者总有效率差异不明显,但在第2个疗程末前者完全缓解率达77.2%,后者仅23.4%,两者差异有显著意义(P＜0.005).结论:冷灸治疗类风湿性指间关节炎效果优于西药抗炎剂.     

Clinical analysis of knee osteoarthritis treated mainly by acupuncture

目的:了解不同治疗方法对膝关节骨关节炎的临床治疗效果.方法:对148例患膝随机分为4组进行针灸、中药频谱照射法、综合法、西药内服治疗,观察其疗效.结果:4组总有效率分别为78.9%,72.7%,92.3%和78.9%,各组之间无差异(P＞0.05).综合组显效率优于其他各组(P＜0.05).结论:针灸、中药频谱照射对膝骨关节炎有一定疗效,综合法能协同两者作用,使疗效提高.     

Treatment of 30 cases of vitiligo by cupping method plus external application of Chinese herbs

在皮损区拔罐,然后外涂中药治疗白癜风患者30例,对照组予西药治疗,3个疗程后,治疗组总有效率96.7%,对照组总有效率76.7%.治疗组疗效好于对照组(P＜0.05).     

Treatment of 30 cases of rheumatoid arthritis by needle-warming therapy

取双侧肾俞、足三里和曲池,进行温针,并配合内服中药治疗类风湿性关节炎患者30例,以西药常规治疗30例为对照.治疗3个月后,两组有效率分别为86.7%和60.0%,疗效差异有统计意义(P＜0.05).     

Clinical observation on scapulohumeral periarthritis treated by Tuina and SSP meridian therapeutic apparatus

目的:观察推拿结合经脉治疗仪治疗肩周炎的疗效.方法:观察组采用推拿结合日本产SSP经脉治疗仪治疗肩周炎患者35例.对照组单纯用经脉治疗仪治疗肩周炎患者30例.结果:观察组与对照组对肩周炎的治疗都有一定效果.但观察组的治愈率与对照组相比有明显差距(P＜0.01),观察组对肩周炎的治愈率明显高于对照组.结论:经脉治疗仪结合推拿是治疗肩周炎的一种有效方法.     

Treatment of 25 cases of obstruction of Qi in the chest by Tuina

应用一指禅手法为主治疗25例胸痹患者,结果显示推拿对胸痹患者的各种临床症状均有缓解作用,治愈10例,好转14例,无效1例.     

Treatment of Acute Lumbar Sprain with Single Acupoint： A RCT

目的:评价单一穴位治疗急性腰扭伤的治疗效果.方法:根据统一的诊断标准,在多个临床中心进行随机对照研究.全部病例320例经随机数字表法分为针刺后溪穴观察组和针刺腰痛点对照组.对患者的疼痛程度分别由医师和患者进行评分.结果:治疗2个疗程后,观察组和对照组近期有效率分别为89.4%和82.5%,远期有效率分别为95.6%和93.5%.经Ridit分析,近期疗效差异有统计意义(P<0.05),远期疗效差异无统计意义(P>0.05).结论:针刺单一穴位治疗急性腰扭伤疗效确切,取穴简便,后溪穴疗效好于腰痛点.     

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival.

PURPOSE: To evaluate the potential of the new prognostic information gained by analyzing the coexpression of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in cervical cancer patients. EXPERIMENTAL DESIGN: Sixty-eight patients with International Federation of Gynecology and Obstetrics stage IIB squamous cell carcinoma of the uterine cervix, who underwent concurrent chemoradiotherapy between 1993 and 1996, were divided into the following four groups according to their immunoreactivities for EGFR and COX-2 in paraffin-embedded sections: (a). the EGFR-negative/COX-2-negative group (n = 11); (b). the EGFR-negative/COX-2-positive group (n = 8); (c). the EGFR-positive/COX-2-negative group (n = 27); and (d). the EGFR-positive/COX-2-positive group (n = 22). The clinical features, patterns of treatment failure, and survival data in the four groups were compared. RESULTS: Positive immunoreactivity for EGFR and COX-2 was observed in 49 of 68 (72%) and 19 of 68 (28%), respectively. However, no strong correlation was found between the levels of EGFR and COX-2 immunopositivity (R(2) = 0.05, P = 0.07). Patients in the EGFR-positive/COX-2-positive group had a higher likelihood of locoregional recurrence than those in the other three groups (P = 0.02). Of the patients in the four groups, patients positive for both oncoproteins were found to have the worst prognosis with an overall 5-year disease-free survival rate of 55% compared with 91% for the EGFR-negative/COX-2-negative patients, 88% for the EGFR-negative/COX-2-positive patients, and 69% for the EGFR-positive/COX-2-negative patients (P = 0.05, log-rank test). In addition, the synchronous coexpression of the EGFR and COX-2 oncoproteins was found to be an independent prognostic factor by univariate and multivariate analyses (relative risk = 4.0, P = 0.03). CONCLUSIONS: Given these observations, we conclude that the coexpression of EGFR and COX-2 immunoreactivity may be used as a potent molecular risk factor for predicting the poor survival of patients with the International Federation of Gynecology and Obstetrics stage IIB squamous cell carcinoma of the uterine cervix.